证券日报网讯 9月16日晚间，亨迪药业发布公告称，公司于近日收到国家药品监督管理局核准签发的关 于盐酸甲氧氯普胺的《化学原料药上市申请批准通知书》。 （文章来源：证券日报） ...

格隆汇9月16日丨亨迪药业(301211.SZ)公布，近日收到国家药品监督管理局核准签发的关于盐酸甲氧氯 普胺的《化学原料药上市申请批准通知书》。盐酸甲氧氯普胺是一种多巴胺受体拮抗剂，主要用于缓解 恶心、呕吐症状，也可促进胃肠蠕动以改善消化不良、胃排空延迟等问题。 ...

人民财讯9月16日电，亨迪药业（301211）9月16日晚间公告，公司于近日收到国家药品监督管理局核准 签发的关于盐酸甲氧氯普胺的《化学原料药上市申请批准通知书》。该药品是一种多巴胺受体拮抗剂， 主要用于缓解恶心、呕吐症状，也可促进胃肠蠕动以改善消化不良、胃排空延迟等问题。 ...

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methochlorpromazine Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility for improving dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the approval of Methochlorpromazine Hydrochloride, indicating a significant milestone in its product development pipeline [1] - The drug is primarily indicated for the treatment of nausea and vomiting, which could enhance the company's portfolio in the gastrointestinal therapeutic area [1] Industry Summary - The approval of Methochlorpromazine Hydrochloride reflects ongoing regulatory support for new pharmaceutical products in the market, highlighting the importance of innovative treatments for common gastrointestinal issues [1] - The use of dopamine receptor antagonists in managing gastrointestinal symptoms underscores the growing demand for effective therapies in this segment [1]

智通财经APP讯，亨迪药业(301211.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于盐酸甲 氧氯普胺的《化学原料药上市申请批准通知书》。盐酸甲氧氯普胺是一种多巴胺受体拮抗剂，主要用于 缓解恶心、呕吐症状，也可促进胃肠蠕动以改善消化不良、胃排空延迟等问题。 ...

Policy Developments - The National Healthcare Security Administration (NHSA) held the first session of a series of discussions on supporting innovative drugs and medical devices, with over 20 representatives from pharmaceutical companies, research institutions, and medical organizations participating. The meeting emphasized the NHSA's commitment to supporting true innovation and the importance of a comprehensive value assessment for innovative products to enhance healthcare resource utilization and better serve public health [2]. Drug and Device Approvals - Shanghai Pharmaceuticals announced that its subsidiary's tranexamic acid injection has received approval from the National Medical Products Administration (NMPA) after passing the consistency evaluation for generic drugs. This drug is primarily used for various bleeding conditions caused by primary fibrinolysis [4]. - Huason Pharmaceutical received re-registration approval for three drugs from the Chongqing Drug Administration, including Ganqi Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets [5]. - Huiren Pharmaceutical's subsidiary received approval for the listing of methochlorpromazine hydrochloride raw materials, which are used for preventing postoperative nausea and vomiting, as well as treating nausea related to migraines and radiation therapy. Additionally, the subsidiary received a medical device registration certificate for a sterile, single-use syringe [6]. Capital Market Activities - ST Jingfeng announced the sale of a 51% stake in its subsidiary Jiangxi Yanhua Pharmaceutical to Jiangxi Shaoyang Pharmaceutical for a price of 142,500 yuan. Following this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements [8]. Industry Events - Sichuan University West China Hospital successfully completed the first implanted brain-machine interface surgery in Western China for a patient with spinal cord injury, allowing the patient to control a mechanical hand using brain signals [10][11]. - Samsung Medical's subsidiary signed a procurement framework contract in Brazil worth approximately 341 million yuan, which represents 2.33% of the company's audited revenue for 2024 [12].